Hidden Aggressive Cells Explain Why Some Childhood Cancers Become Fatal Despite Low-Risk Labels

Scientists discovered that some rhabdomyosarcoma tumors classified as low-risk contain hidden, highly aggressive cancer cells, explaining unexpected treatment failures. This finding could lead to earlier detection and more personalized therapies, reducing unnecessary chemotherapy while improving survival rates. The research focuses on a rare childhood soft tissue cancer with genetic origins in early development.

In October 2026, scientists from the Wellcome Trust Sanger Institute, University of Cambridge, Great Ormond Street Hospital (GOSH), and University College London published findings in *Cancer Research* revealing that some rhabdomyosarcoma (RMS) tumors labeled as low-risk still harbor hidden, highly aggressive cancer cells. The study analyzed tumor samples from 16 children—four with fusion-negative but fatal RMS, four with fusion-positive disease, and eight with fusion-negative survival cases. Using single-cell RNA sequencing and spatial transcriptomics, researchers detected gene activity patterns in non-high-risk tumors that mirrored those of the most aggressive forms, despite lacking the well-known genetic fusion marker. This discovery helps explain why some children with seemingly low-risk diagnoses experience rapid disease progression or death. RMS is a rare soft tissue cancer affecting children under 15, with about 55 new cases annually in the UK. Unlike adult cancers shaped by aging or environment, childhood cancers like RMS often stem from developmental genetic errors. The current risk classification system relies heavily on the presence of a specific gene fusion, but this study shows that aggressive behavior can emerge through alternative genetic pathways, challenging the reliability of existing prognostic tools.

The research team, led by Dr. Karin Straathof of UCL Cancer Institute and GOSH, aims to shift cancer diagnosis toward identifying biological signatures of ag